Cosyntropin | CAS# 16960-16-0 | synthetic peptide

MedKoo Cat#: 413289 | Name: Cosyntropin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cosyntropin is a synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.

Chemical Structure

Cosyntropin

CAS#16960-16-0

Theoretical Analysis

MedKoo Cat#: 413289

Name: Cosyntropin

CAS#: 16960-16-0

Chemical Formula: C136H210N40O31S

Exact Mass: 2931.5806

Molecular Weight: 2933.49

Elemental Analysis: C, 55.68; H, 7.22; N, 19.10; O, 16.91; S, 1.09

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cosyntropin; Tetracosactide; Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro

IUPAC/Chemical Name

L-Seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valylglycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline

InChi Key

ZOEFCCMDUURGSE-CQVUSSRSSA-N

InChi Code

InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1

SMILES Code

O=C(O)[C@H]1N(C([C@H](CC2=CC=C(O)C=C2)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H]3N(C([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CCCCN)NC(CNC([C@H](C(C)C)NC([C@H]4N(C([C@H](CCCCN)NC(CNC([C@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CCCNC(N)=N)NC([C@H](CC7=CC=CC=C7)NC([C@H](CC8=CNC=N8)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CO)NC([C@H](CC9=CC=C(O)C=C9)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC4)=O)=O)=O)=O)=O)=O)=O)CCC3)=O)=O)=O)=O)=O)CCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Tetracosactide (INN) is an analogue of adrenocorticotrophic hormone (ACTH), with the biological activity of stimulating production of corticosteroids in the adrenal cortex.

In vitro activity:

TBD

In vivo activity:

Reduced numbers of MPO+ cells were also found in the perilesional cortex and hippocampus in CoSyn (cosyntropin) treated TBI mice compared to their saline-treated counterparts. Furthermore, CoSyn treatment reduced IL1β expression in the cortex of TBI mice. Behavioral testing showed a treatment effect of CoSyn for NOR with CoSyn increasing the discrimination ratio in both TBI and Sham groups, indicating increased memory performance. CoSyn also decreased latency to find platform during the early training period of the MWM when comparing CoSyn to saline-treated TBI mice suggesting moderate improvements in spatial memory following CoSyn treatment. Reference: Front Mol Neurosci. 2020 Jun 26;13:109. https://pubmed.ncbi.nlm.nih.gov/32670020/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	34.09

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 2,933.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Siebold L, Krueger AC, Abdala JA, Figueroa JD, Bartnik-Olson B, Holshouser B, Wilson CG, Ashwal S. Cosyntropin Attenuates Neuroinflammation in a Mouse Model of Traumatic Brain Injury. Front Mol Neurosci. 2020 Jun 26;13:109. doi: 10.3389/fnmol.2020.00109. PMID: 32670020; PMCID: PMC7332854.

In vitro protocol:

TBD

In vivo protocol:

1: Pizzolo F. Primary aldosteronism diagnosis: is cosyntropin stimulation in adrenal venous sampling still convincing? J Hypertens. 2021 Nov 1;39(11):2139-2140. doi: 10.1097/HJH.0000000000002955. PMID: 34620807. 2: Kozyra EF, Wax RS, Burry LD. Can 1 microg of cosyntropin be used to evaluate adrenal insufficiency in critically ill patients? Ann Pharmacother. 2005 Apr;39(4):691-8. doi: 10.1345/aph.1E139. Epub 2005 Mar 1. PMID: 15741424. 3: Rossi GP. Heterogenous Responses to Cosyntropin in Primary Aldosteronism. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz133. doi: 10.1210/clinem/dgz133. PMID: 31665321. 4: Zapapas MK, Gralla J, Tong S, Eisdorfer S. Cosyntropin for the Treatment of Refractory Postdural Puncture Headache in Pediatric Patients: A Retrospective Review. Clin J Pain. 2020 Mar;36(3):213-218. doi: 10.1097/AJP.0000000000000784. PMID: 31789828. 5: Knupp KG, Coryell J, Singh RK, Gaillard WD, Shellhaas RA, Koh S, Mitchell WG, Harini C, Millichap JJ, May A, Dlugos D, Nickels K, Mytinger JR, Keator C, Yozawitz E, Singhal N, Lockrow J, Thomas JF, Juarez-Colunga E. Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial. J Child Neurol. 2022 Mar;37(3):186-193. doi: 10.1177/08830738211073400. Epub 2022 Jan 19. PMID: 35044272. 6: Magnotti M, Shimshi M. Diagnosing adrenal insufficiency: which test is best-- the 1-microg or the 250-microg cosyntropin stimulation test? Endocr Pract. 2008 Mar;14(2):233-8. doi: 10.4158/EP.14.2.233. PMID: 18308665. 7: Blum CA, Schuetz P, Nigro N, Winzeler B, Arici B, Refardt J, Urwyler SA, Rodondi N, Blum MR, Briel M, Mueller B, Christ-Crain M. Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial. Clin Endocrinol (Oxf). 2019 Sep;91(3):374-382. doi: 10.1111/cen.13907. Epub 2019 Jan 9. PMID: 30485501. 8: Hakim SM. Cosyntropin for prophylaxis against postdural puncture headache after accidental dural puncture. Anesthesiology. 2010 Aug;113(2):413-20. doi: 10.1097/ALN.0b013e3181dfd424. PMID: 20613476. 9: Ben-Shlomo A, Guzman J, Mirocha J. Enhanced cosyntropin stimulation test performance enabled by electronic medical record. Pituitary. 2016 Oct;19(5):503-6. doi: 10.1007/s11102-016-0731-4. PMID: 27259503. 10: Lentz S, Collier KC, Willis G, Long B. Diagnosis and Management of Adrenal Insufficiency and Adrenal Crisis in the Emergency Department. J Emerg Med. 2022 Aug;63(2):212-220. doi: 10.1016/j.jemermed.2022.06.005. Epub 2022 Aug 26. PMID: 36038436. 11: Discussion. Surgery. 2016 Jan;159(1):265-6. doi: 10.1016/j.surg.2015.05.037. Epub 2015 Sep 28. PMID: 26422763. 12: O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. PMID: 27838190. 13: Abu-Ahmad A, Shechner C, Sheikh-Ahmad M, Reut M, Chen-Konak L, Jiries N, Saiegh L. Performance of low-dose cosyntropin stimulation test in the afternoon. Minerva Endocrinol. 2019 Sep;44(3):241-245. doi: 10.23736/S0391-1977.18.02890-0. Epub 2018 Sep 24. PMID: 30256074. 14: Peechakara S, Bena J, Clarke NJ, McPhaul MJ, Reitz RE, Weil RJ, Recinos P, Kennedy L, Hamrahian AH. Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study. Endocrine. 2017 Sep;57(3):388-393. doi: 10.1007/s12020-017-1371-9. Epub 2017 Jul 20. PMID: 28730418. 15: DeClue AE, Martin LG, Behrend EN, Cohn LA, Dismukes DI, Lee HP. Cortisol and aldosterone response to various doses of cosyntropin in healthy cats. J Am Vet Med Assoc. 2011 Jan 15;238(2):176-82. doi: 10.2460/javma.238.2.176. PMID: 21235369. 16: Dreijerink KM, Kampschreur LM, Lentjes EG, Lokhorst B, Zelissen PM. Atypical hypocortisolism. Endocr Pract. 2013 Sep-Oct;19(5):e112-4. doi: 10.4158/EP12415.CR. PMID: 23757611. 17: Cattet M, Janz DM, Kapronczai L, Erlenbach JA, Jansen HT, Nelson OL, Robbins CT, Stenhouse GB. Cortisol levels in blood and hair of unanesthetized grizzly bears (Ursus arctos) following intravenous cosyntropin injection. Vet Med Sci. 2021 Sep;7(5):2032-2038. doi: 10.1002/vms3.523. Epub 2021 May 12. PMID: 33978314; PMCID: PMC8464257. 18: Hurel SJ, Kendall-Taylor P, Baylis PH. Pituitary tumours. BMJ. 1994 Jul 9;309(6947):130. doi: 10.1136/bmj.309.6947.130b. PMID: 8038662; PMCID: PMC2540585. 19: Turcu AF, El-Maouche D, Zhao L, Nanba AT, Gaynor A, Veeraraghavan P, Auchus RJ, Merke DP. Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation. Eur J Endocrinol. 2020 Jul;183(1):63-71. doi: 10.1530/EJE-20-0129. PMID: 32487778; PMCID: PMC7458124. 20: Martin LG, Behrend EN, Mealey KL, Carpenter DM, Hickey KC. Effect of low doses of cosyntropin on serum cortisol concentrations in clinically normal dogs. Am J Vet Res. 2007 May;68(5):555-60. doi: 10.2460/ajvr.68.5.555. PMID: 17472457.